Dr. Keith Wilner
Dr. Wilner received his B.A. in chemistry at KU carrying out undergraduate research in the laboratories of Professor Rich Givens and Professor Ralph Christofferson. After graduation, he earned a Ph.D. in pharmacology from the University of Texas Health Science Center at Houston followed by postdoctoral studies at the University of California, San Diego. Dr. Wilner joined Pfizer Global Research and Development in 1986 as a Clinical Research Scientist. He was promoted to Senior Investigator at Pfizer in 1989, Associate Director in 1991, Director in 1997, and Senior Director in 2001. In 2016, Dr. Wilner was named Global Clinical Lead for the clinical development of Crizotinib and Palbociclib. Between 2017 and 2019 his portfolio of clinical leads expanded and in 2022 he was named Global Clinical Lead, Lung Cancer and DMD, GPD/Oncology and Rare Diseases.